Thank you, Chair, and thank you to the witnesses for your testimony to date.
As I'm sure you know, the goal of this particular study is to provide the federal government with very practical, focused recommendations on how to improve pharmaceutical sovereignty in Canada. You've given us some hints of this already during your testimony, but starting with you, Monsieur Thibeault, could you give us one or two absolute priority areas from your perspective to assist us?